Literature DB >> 15165748

Signaling pathways involved in the development of cannabinoid tolerance.

Billy R Martin1, Laura J Sim-Selley, Dana E Selley.   

Abstract

Considerable plasticity exists in the endogenous cannabinoid system, as evidenced by the high degree of tolerance that develops following repetitive exposure to exogenously administered cannabinoid receptor agonists. This tolerance development is accompanied by cannabinoid CB(1) receptor downregulation and attenuation of G-protein activation. The biological processes responsible for CB(1) receptor downregulation remain to be fully understood. However, recent evidence suggests that several protein kinases participate in the development of cannabinoid tolerance. These observations implicate a role for protein kinases in cannabinoid signaling pathways. It remains to be established whether these protein kinases are directly involved in CB(1) receptor regulation or whether they contribute to tolerance by modulating additional signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165748     DOI: 10.1016/j.tips.2004.04.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  37 in total

Review 1.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling.

Authors:  Tanya L Daigle; Christopher S Kearn; Ken Mackie
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

Review 3.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

4.  Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.

Authors:  Caitlin M Nealon; Angela N Henderson-Redmond; David E Hale; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-01-08       Impact factor: 5.250

5.  CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Authors:  Liting Deng; Benjamin L Cornett; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

6.  The CB1 cannabinoid receptor C-terminus regulates receptor desensitization in autaptic hippocampal neurones.

Authors:  Alex Straiker; Jim Wager-Miller; Ken Mackie
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

7.  Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions.

Authors:  Mathieu Lafourcade; Thomas Larrieu; Susana Mato; Anais Duffaud; Marja Sepers; Isabelle Matias; Veronique De Smedt-Peyrusse; Virginie F Labrousse; Lionel Bretillon; Carlos Matute; Rafael Rodríguez-Puertas; Sophie Layé; Olivier J Manzoni
Journal:  Nat Neurosci       Date:  2011-01-30       Impact factor: 24.884

Review 8.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

10.  PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2.

Authors:  Melisa J Wallace; Philip M Newton; Thomas McMahon; Jacklyn Connolly; Anne Huibers; Jennifer Whistler; Robert O Messing
Journal:  Neuropsychopharmacology       Date:  2009-01-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.